PTC Therapeutics Inc (NASDAQ:PTCT)

72.72
Delayed Data
As of Mar 05
 +2.27 / +3.21%
Today’s Change
14.51
Today|||52-Week Range
75.94
+40.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.4B

Company Description

PTC Therapeutics, Inc. is a biopharmaceutical company, which is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. It's preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology andinfectious disease. The company's lead product candidate ataluren is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Contact Information

PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield New Jersey 07080
P:(908) 222-7000
Investor Relations:
(908) 912-9167

Employees

Shareholders

Mutual fund holders51.15%
Other institutional35.58%
Individual stakeholders27.81%

Top Executives

Stuart W. PeltzChief Executive Officer & Director
Shane William Charles KovacsChief Financial Officer
Neil Gregory AlmsteadSVP-Research, Chemistry, Manufacturing & Controls
Robert Jay SpiegelChief Medical Officer
Mark Elliott BouldingSecretary, Chief Legal Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account